Colchicine and Spironolactone in Patients With MI / SYNERGY Stent Registry
Status:
Recruiting
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat
myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY
stent) as well as the non-culprit arteries (randomization to routine colchicine and
spironolactone).
Phase:
Phase 3
Details
Lead Sponsor:
Population Health Research Institute
Collaborators:
Boston Scientific Corporation BSC Canadian Institutes of Health Research (CIHR)